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ABSTRACT
Objective: To identify which enteral nutrition (EN) formulations are currently
recommended in the acute care setting by registered dietitians (RDs) in New Mexico for
patients with active Crohn’s Disease (CD) and to compare these recommended
formulations to the ASPEN and ESPEN guidelines.
Methods: The link to an electronic survey was e-mailed to 109 potentially eligible RDs
employed at acute care facilities in New Mexico during the spring of 2011. E-mail
addresses were obtained from the Commission on Dietetic Registration. Descriptive
statistics, Fisher’s exact, Pearson’s χ2 and Cramer’s V tests (SPSS; version 21) were used
to analyze relationships between variables.
Results: Twenty-three participants fit the inclusion criteria and completed the survey
(42.6% response rate). All eligible participants were 26 to 64 years of age, 82.6% were
females, 91.3% were Caucasian, 56.5% worked at an urban location, 69.6% had been
practicing dietetics for more than 15 years and 56.5% worked solely with adult patients.
Seventy-four percent of RDs reported using semi-elemental and elemental EN
formulations. ASPEN (26%), ESPEN (22%) and AND NCM (22%) guidelines were the
most commonly reported guidelines used by RDs. RDs employed at a rural locations
(26.1%) were more likely to report access challenges (p = .025). Practicing dietetics for
less than 15 years (34.8%) was statistically associated with the use of ESPEN guidelines
(p = .016). RDs that reported using ASPEN and ESPEN guidelines (40%) did not
necessarily recommend polymeric EN formulations for patients with active CD (p =
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.382). RDs that reported using ASPEN guidelines (67%) were more likely to report using
polymeric EN formulations (p = .025).
Conclusion: RDs employed at acute care facilities in New Mexico generally recommend
semi-elemental and elemental EN formulations for patients with active CD, even though
the ASPEN and ESPEN guidelines recommend the use of polymeric EN formulations.
This study demonstrated that access issues, limited available research and physician
resistance to the use of EN may be factors associated with decreased use of EN in
patients with active CD. Further research on the use of EN in patients with active CD
should be conducted, so that evidence-based guidelines can be developed.
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CHAPTER 1: INTRODUCTION
Crohn’s disease (CD), also known as regional enteritis, is a disease that was first
described by Dr. Burrill B. Crohn and his colleagues in a paper published in 1932 (1).
CD is a type of inflammatory bowel disease (IBD) that can affect any part of the
gastrointestinal (GI) tract. The two major types of IBD are ulcerative colitis and CD. CD
can affect the entire thickness of the small intestinal wall and typically occurs in the
ileum and the proximal large intestine (2). Unlike CD, ulcerative colitis only involves the
colon and does not affect all layers of the intestinal wall. CD can skip portions of the
intestines leaving healthy, unaffected portions in between patches of diseased intestine
(3). CD typically consists of two phases: active and remission (3). CD is considered
active when symptoms are present or a patient has a score of greater than 150 using the
Crohn’s Disease Activity Index (CDAI) on a scale of 0 to 600 (4). CD symptoms in
adults can differ from those in the pediatric population. CD symptoms in adults may
include diarrhea, cramping, fever, abdominal pain, nausea, decreased appetite, weight
loss, fatigue and rectal bleeding (5, 6). In the pediatric population, delayed onset of
puberty and poor linear growth, weight gain and bone mineralization may be the primary
symptoms of CD (2, 7). CD is an idiopathic and incurable chronic condition, but it can
be managed with medications, surgery, nutrition support or a combination of these
therapies.

There are five types of CD that are classified according to the location in the GI tract
where the disease occurs (5). Granulomatous colitis only affects the large intestine, while
gastroduodenal CD affects both the stomach and duodenum and Crohn’s ileitis affects the
ileum. The most common type of CD is ileocolitis and it affects the large intestine and
ileum. Lastly, jejunoileitis produces patches of inflammation in the jejunum. CD can
cause severe complications, with voluminous diarrhea and corrosion caused by excessive
secretion of digestive enzymes leading to fluid and electrolyte imbalances and nutrient
deficiencies and promotion of the development of fistulas and intestinal obstructions (5,
8, 9, 10).
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The prevalence and incidence of CD have been increasing in Western countries since the
1970’s (11). The prevalence of CD in the United States (US) is approximately 320 out of
100,000 people (11). CD is most frequently diagnosed between the ages of 15 and 30
years, but it may be diagnosed at any age (2). There is a slight predominance of the
female gender being diagnosed with CD. Caucasians, especially those of Eastern
European Jewish descent appear to develop CD more often than other ethnicities (6).

The etiology of CD is complex. A combination of environmental, genetic and
autoimmune factors is thought to contribute to the development of CD (12). Cigarette
smoking has been found to be a risk factor in the development of CD and may promote
an exacerbation of CD (11). On the other hand, being breastfed in infancy may reduce
the risk of developing CD in adulthood (7). It is theorized that a Westernized diet high in
saturated fat and processed foods may have an influence in the development of CD due to
the presence of pro-inflammatory substances in a Westernized diet (9, 13, 14).

Nutritional therapy in addition to surgical, medical or pharmacological therapies is
important in the treatment of active CD (3). Nutritional therapies (Table 1) may include
parenteral nutrition (PN), enteral nutrition (EN), medical nutrition therapy (MNT) or a
combination of these therapies (15, 16, 17). EN has been found to stimulate remission in
approximately 53 to 84% of individuals with active CD when used exclusively or as an
adjunct to corticosteroids (8, 18). However, EN appears to be more effective in inducing
and maintaining remission in pediatric patients than in adults with CD and is more
commonly used in the pediatric population (19).
Nutritional Therapy
Parenteral Nutrition (PN)
Enteral Nutrition (EN)
Medical Nutrition Therapy
(MNT)

Table 1: Types of Nutritional Therapies
Description
 Nutrition is provided through an intravenous tube called a catheter
that is directly inserted into the veins (17).
 Nutrition is provided through a feeding tube into the GI tract (17).


Nutrition assessment, intervention, monitoring and evaluation
provided by a registered dietitian (RD) to manage a specific disease
state (e.g. IBD) through diet (20).

Approximately 75% of hospitalized patients with active CD have unintentional weight
loss (15, 17). Unintentional weight loss, specifically more than 10% of total body weight
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in a period less than 6 months in an underweight individual, may deplete nutritional
reserves and put the individual at risk for malnutrition. An individual with unintentional
weight loss may greatly benefit from nutrition therapy, such as oral nutrition supplements
or EN (15, 21). Malnutrition may impair the functions of the GI, cardiac, pulmonary,
renal and immune systems; hence hindering healing, increasing the risk of health
complications and predisposing an individual to a decreased quality of life (QOL) and
loss of independence (21). EN support either as an adjunct to oral nutrition or as sole
nutrition is the therapy of choice in malnourished patients with active CD (15). If a
patient requires exclusive EN and does not tolerate EN support for five days, it is
recommended that PN be initiated (12). However, bowel rest may not be necessary in
most patients with CD because it does not seem to affect remission in CD (17).

The mechanism by which EN induces a remission in some patients is unclear, but may be
due to: 1) exclusion of pro-inflammatory dietary components present in oral diets, 2)
changes in bacterial flora, 3) reduction of total fat, or 4) the addition of glutamine in EN
formulas that may decrease wound healing time (3, 12). EN is recommended for patients
with active CD if they are intolerant to corticosteroids, refuse corticosteroids, are
undernourished, as an adjunct to corticosteroids and in patients that have inflammatory
stenosis of the intestine (15).

There are three types of EN formulations: elemental, semi-elemental and polymeric
formulations (Table 2). Elemental EN formulations are believed to be less allergenic and
the easiest to absorb with nutrients provided in forms that require minimal digestion prior
to absorption: nitrogen in the form of amino acids, carbohydrate as monosaccharides and
fats primarily from medium-chain triglycerides (MCT) (8, 17). The limitation of
elemental EN formulations is their decreased palatability and increased cost. Semielemental formulations contain nitrogen as partially hydrolyzed protein blends (peptides),
glucose polymers (sucrose or maltodextrin) and fat mostly as MCTs. Research is lacking
in the effectiveness of semi-elemental formulations in inducing remission in patients with
CD. On the other hand, polymeric formulations are generally more palatable and less
expensive. Polymeric formulations contain nitrogen in the form of whole proteins,
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carbohydrates as hydrolysates of starch and fat from oils mostly in the form of long-chain
triglycerides (LCT) and may be more difficult to digest and absorb in a person with a
damaged intestinal mucosa.
Table 2: Breakdown of Macronutrient Content of the Types of EN Formulations
Types of EN
Protein Content

Polymeric Formulation
 Intact proteins or peptides
 Usually from cow’s milk or
soybeans
 Polyunsaturated fatty acids from
corn, safflower, sunflower or
soybean oil or from animal fat

Semi-Elemental Formulation
 Peptides or a combination of
peptides and amino acids

Elemental Formulation
 Amino acids





Medium-chain triglycerides

Carbohydrate
Content







Monosaccharides

Advantages










Easier to digest
Easier to absorb
Decreased palatability
High osmotic load of simple
sugars and amino acids
Increased cost

Fat Content

Disadvantages



Maltodextrin and hydrolyzed
cornstarch, glucose-derived
saccharides or corn syrup
Increased palatability
Decreased cost
Nutrients must be broken down
prior to absorption
May not be tolerated by the
patient






A proportion of medium-chain
triglycerides is usually
provided to improve fat
absorption
Carbohydrate complexity varies
and is generally lactose-free
(sucrose or maltodextrin)
Easier to digest
Easier to absorb
Increased cost
Decreased palatability



Researchers have investigated the effectiveness of the different EN formulations in
inducing remission in patients with active CD (22, 23). Evidence suggests that patients
receiving an exclusive diet of a polymeric EN formulation may have similar remission
rates to those who receive their sole nutrition from an elemental EN formulation (22).
Polymeric formulations are generally more palatable and less expensive than elemental
formulations, so they are generally recommended for use as an oral supplement in
patients with active CD (15, 22).

Benefits of using EN as a therapy for CD include improved weight, improved QOL,
promotion of intestinal mucosal healing, promotion of beneficial bacterial flora in the
intestine, reduction of the exposure of the mucosa to antigens, improved absorption of
nutrients and resolution of protein loss (3, 9). Additionally, the use of EN is correlated
with reduction in levels of pro-inflammatory cytokines (9). Elemental EN formulations
may be beneficial for patients with CD because it has been observed that there are
reduced total bacteria per gram in patient’s feces receiving an elemental EN formulation
compared to a polymeric formulation (14, 17). Animal studies have demonstrated that
animals raised in a germ-free environment do not develop intestinal disease, thus
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suggesting that use of exclusive EN may prevent a CD exacerbation due to decreased
antigen exposure (24). Additionally, exclusive consumption of an elemental EN
formulation may allow for bowel rest and some studies have found remission rates to be
as high as 84% in patients consuming an exclusive diet of elemental EN (25).

The European Society for Parenteral and Enteral Nutrition (ESPEN) published guidelines
in 2006, which recommend EN for patients who are undernourished and in the active
stage of CD (15). Polymeric formulations are recommended as the first nutritional
therapy of choice and if symptoms of intolerance (diarrhea, constipation, abdominal
distention, abdominal pain, nausea or vomiting) develop, then elemental EN formulations
should be utilized (15, 26). The American Society for Parenteral and Enteral Nutrition
(ASPEN) published guidelines that are similar to ESPEN guidelines with respect to the
recommendations regarding the promotion of EN in patients who cannot consume
adequate nutrition orally (15, 16). Additionally, both ASPEN and ESPEN guidelines
recommend polymeric EN formulations as the primary nutrition therapy of choice, as
there appears to be no significant difference between the types of EN formulations in
inducing remission (16).

Hospitalization is not uncommon in individuals suffering with CD, especially those with
severe exacerbations of their disease. Utilizing MNT during active CD may improve
clinical outcomes (27). The risk of developing malnutrition during acute exacerbations
increases due to frequent medical procedures, need for bowel rest, severe diarrhea,
nutrient malabsorption and hospital acquired infections. Malnutrition is associated with
negative outcomes, such as decreased lean body mass, weight loss, poor wound healing
and decreased immune function, which can increase hospital length of stay (13, 28).
Improving the nutritional status of patients with CD is a major goal. Consultation with a
registered dietitian (RD) is associated with improved medical efficiency, decreased
nutrition-related hospitalizations and improvement in nutritional management (29). In
general, it has been found that specialized nutrition support is cost-effective and may
prevent infectious complications as well as decrease the patient’s duration of
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hospitalization by 51% (27). However, there is no published data on the role of the RD
in the treatment of patients with active CD.

RD intervention may play an important role in the MNT for a patient with active CD.
The RD can use MNT for the prevention of malnutrition, improvement of nutritional
status, and promotion of remission and gut healing in patients with active CD (30).

To date, there are no published studies regarding whether RDs utilize current clinical
nutrition recommendations (ASPEN or ESPEN) for the use of EN in patients with active
CD or what, if any, guidelines they currently use in the acute care setting. The purpose of
this study was to compare the EN formulations that are currently recommended in the
acute care setting by RDs in New Mexico who provide MNT for patients with active CD
to the current ESPEN and ASPEN guidelines. For this study, an acute care facility was
considered to be an accredited health care facility in New Mexico that admits patients for
overnight stays for medical treatment. The hypothesis of this study was that RDs that
work in acute care facilities in New Mexico follow the current clinical nutrition
guidelines (ASPEN and ESPEN) and recommendations for EN support in patients with
active CD.
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CHAPTER 2: REVIEW OF THE RELATED LITERATURE
The purpose of this literature review is to summarize the most recent published literature
on the use of EN support both as an adjunct to an oral diet and as the sole nutritional
therapy in the treatment of patients with active CD. In addition, current EN guidelines
for CD will be reviewed, as well as the role the RD plays in the MNT for patients with
active CD. There are multiple therapies available for CD with the goal of reducing
inflammation and the symptoms associated with the disease as well as prolonging the
periods of remission between active CD exacerbations (3). Limited published research
has focused on the use of EN support for either sole therapy or as an adjunct to surgical
and pharmacological therapies. This literature review will focus on the use of EN as a
therapy in adult patients with active CD. Pediatric studies will be discussed as well, due
to the limited published research conducted on adult patients with CD.
Benefits of EN Therapy in the Treatment of Active CD
CD incidence in the US has increased in the twentieth century, which may be related to
the increased intake of potentially pro-inflammatory substances (saturated fat, sugar and
sodium) found in processed and fast food, which are commonly consumed in Western
diets (9, 13, 14). Western diets also contain large amounts of dust and food additives,
which may promote an immune response when consumed (14). EN as a sole source of
nutrition allows for the avoidance of substances in the Western diet that may be proinflammatory, which could potentially cause an exacerbation of CD in those with an
already damaged intestinal mucosa (3, 13). Evidence suggests that EN therapy may
promote remission in adults with active CD and that it should be utilized more frequently
to prevent active CD and maintain remission in these individuals (30).

Another theory behind the pathogenesis of CD is that some bacteria in our environment
are transmitted to the gut (i.e. via food consumption) and may promote the inflammatory
process that is observed in CD (19). In CD, there is an increase in intestinal permeability
due to abnormalities in the tight junctions found between enterocytes in the intestines
(17). This may allow for antigen-uptake and promotion of bacterial growth, which
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encourages the inflammation observed in CD. In patients with IBD, there are a larger
number of bacteria in contact with the intestinal mucosa (12). Interestingly, IBD lesions
occur in segments with the highest concentrations of bacteria, which is in the ileo-cecal
valve and the colon. Surgery involving removal of this part of the GI tract for CD
patients decreases the rate of relapse of CD (12). One group of investigators found that a
diet consisting of an exclusive elemental EN formulation may be beneficial for patients
with CD because it was observed that there were reduced total bacteria per gram in
patient’s feces who received an exclusive diet of an elemental EN formulation, hence EN
may promote remission and decrease the inflammatory process observed in CD (3, 31).
Evaluation of the use of EN Therapy as a Treatment for Patients with Active CD
The effectiveness of utilizing diets consisting of polymeric, semi-elemental and elemental
EN formulations to achieve and maintain remission in patients with active CD has been
evaluated (22). These formulations have many important differences including the
macronutrient composition and cost. Elemental and semi-elemental formulations can
cost up to 400% more than standard polymeric formulations (8). The premise behind the
use of elemental EN formulations is that patients with CD, who have a damaged
intestinal mucosa, have a reduced ability to secrete digestive enzymes for adequate
absorption of nutrients and villous atrophy, which may reduce absorptive capacity.

Semi-elemental and elemental EN formulations are more easily absorbed, less allergenic
and better tolerated in malabsorptive states than polymeric formulations because they
require minimal digestion prior to absorption (8, 14, 23). Polymeric formulations provide
nitrogen as a whole protein and are considered standard formulations. Polymeric
formulations are less expensive, more palatable and are generally recommended as the
primary EN formulation of choice (15).
The Role of EN in Inducing Remission During Active CD
The use of EN in the pediatric population is the preferred therapy for active CD because
corticosteroids may impair children’s linear growth (13). An estimated 20 to 30% of
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children under the age of 16 years taking corticosteroids for CD have an abnormally short
stature later in life (13, 19).

Day et al. (19) demonstrated the benefits of EN in inducing remission and improving
nutritional status in pediatric patients with active CD. This study consisted of 27 male
children between the ages of three and 16 years with active CD who consumed an
exclusive diet consisting of a standard polymeric EN formulation (varying amounts of
Osmolite or Modulen IBD depending on weight gain) for 6 – 8 weeks. Eighty-nine
percent of the children completed the study by consuming an exclusive EN diet for 6 – 8
weeks (n = 12 with longstanding CD and n = 12 with newly diagnosed CD). Nineteen
children consumed the EN orally (80%) without the need for insertion of a naso-gastric
(NG) feeding tube. Seventy-nine percent of the children who completed the study
entered remission, which was based on the Pediatric CDAI (on a scale of 0 to 80), with a
score of less than 15 indicative of remission. Gradually, a normal diet was reintroduced
during the 15.2-month follow-up. Eleven patients elected to continue supplementary EN
(300 – 2750 ml/day without other medical therapies in four participants and in addition to
other medical therapies in seven children) in addition to their oral diet. This study
reported improved standard inflammatory markers (e.g. erythrocyte sedimentation rate
[27.83 vs. 17.62 mm/h, < .04], C-reactive protein [29.19 vs. 5.38 mg/L, p < .002],
albumin [31.14 vs. 35.43 g/L, p < .02] and platelets [407 vs. 331.5 x109/L, p < 0.049]) in
all patients that entered remission. None of the children lost weight during this study;
however, by eight weeks, the children with long-standing CD that achieved remission (n
= 7, 58%) gained an average of 4.86 kg compared to 2.29 kg in the children who did not
(n = 5, p < 0.05). Also, the children with newly diagnosed CD who achieved remission
(n = 12, 100%) gained an average of 4.7 kg compared to 0.75 kg in children that did not
complete their course of exclusive EN (n = 3, p < .05). Linear growth of up to 3 cm was
documented in this study; however, there was no change in height Z scores over the 6 – 8
week period. A limitation of this study was that the range of 300 to 2750 ml daily of EN
is a large range and would have resulted in a huge variance in the amount of calories and
nutrients consumed from the EN formulations. The results of this study show that a diet
consisting exclusively of a polymeric EN formulation can induce remission during an
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exacerbation of CD, improve nutrition status, prevent weight loss and result in an
improvement of inflammatory markers in patients with active CD.

Borelli et al. (23) evaluated the efficacy of exclusive EN therapy (no other treatment) to
that of corticosteroid therapy as treatments for pediatric patients with active CD. This
prospective trial consisted of 37 children (ages four to 17 years of age) who were
randomly assigned to consume an exclusive polymeric EN diet (n = 19) or were provided
oral corticosteroids with an unrestricted diet (n = 18) over a ten-week period. The
investigators found that there was significant improvements of mucosal healing, which
was measured via the Crohn’s Disease Endoscopy Index of Severity and a histological
scoring system, in the children consuming polymeric EN compared to the children that
received an unrestricted diet with corticosteroids (74% vs. 33% of patients that were on
corticosteroids exclusively, p < 0.05). Intestinal healing was assessed by an endoscopy
and histology at baseline and at the end of the study. Limitations of this study include the
small sample size that may have led to a lack of generalizability, the study was not
blinded and the subjects were provided different dosages of EN and corticosteroids
depending on the requirement of each patient. Borelli’s data support the use of a
polymeric formulation in children with active CD because use of polymeric EN
formulations lead to increased mucosal healing. Lastly, the investigators of this study
emphasized the need for dietary measures that can prolong remission and decrease the
need for pharmacotherapy and surgical interventions in CD.

In a randomized controlled trial (RCT) conducted by Mansfield et al. (32), subjects were
randomly assigned to receive an exclusive diet of semi-elemental or elemental EN
formulations via NG feeding tubes for 28 days. The purpose of this study was to assess
the effectiveness of elemental and semi-elemental formulations as sole nutritional
therapies for adults with active CD. This study included 44 participants (63% males and
37% females). Twenty-two participants were randomized to the elemental diet group and
the other 22 participants were given the semi-elemental formulation. All medical
treatments, including corticosteroids that patients were receiving prior to the study, were
gradually withdrawn during the first 12 days of the study. All participants received the
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EN via an NG feeding tube with no other oral intake. The EN consisted of an exclusive
semi-elemental (oligopeptide, as the protein source; Pepti-2000 LF liquid) or elemental
(nitrogen in the form of amino acids; Elemental 028) EN diet. Sixteen (36.4%)
participants (semi-elemental group n = 8, elemental group n = 8) achieved remission,
which was determined by a reduction of the patient’s CDAI score by 100 points or 40%
of the baseline value, control of symptoms and withdrawal of all treatments the
participant was receiving prior to the study. EN feedings were discontinued in six
(13.6%) subjects due to intolerance to the NG tube and 22 (50%) participants did not
attain clinical remission (11 from each group). The results of this study support the use
of semi-elemental and elemental formulations to promote improvements in CD symptoms
and reduction in intestinal inflammation. A major limitation of this study is that the ages
of the participants were not published. This is a limitation because the human body
functions differently depending on one’s age. An additional limitation is that prior
medical treatments were withdrawn during the study period (there was no washout
period), which may have affected the study’s results; especially since this study was only
conducted over a 28 day period. However, the investigators concluded that elemental EN
formulations are not necessarily more beneficial than semi-elemental formulations in the
treatment of adult patients with active CD.

EN support can be used to induce and maintain remission (17, 22). EN promotes
intestinal healing and improves the nutritional status of CD patients; therefore polymeric
EN formulations as an adjunct to other therapies for active CD should be utilized due to
their cost-effectiveness and increased palatability to encourage increased dietary
compliance.
Clinical Nutrition Guidelines for EN Support in Patients with Active CD
ESPEN Clinical Nutrition Guidelines for CD
The European Society for Enteral and Parenteral Nutrition (ESPEN) is a
multidisciplinary society that is dedicated to the study of metabolic problems associated
with diseases and their nutritional implications (15). ESPEN aims to encourage the rapid
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diffusion of knowledge in the field of clinical nutrition and metabolism. The ESPEN
guidelines published in 2006 state that corticosteroids are a more effective treatment
therapy in adult patients with active CD and that EN as a sole therapy is “indicated
mainly when treatment with corticosteroids is not feasible”, e.g. due to intolerance or
refusal...“combined therapy (EN and drugs) is indicated in undernourished patients as
well as in those with inflammatory stenosis of the intestine” (15). Also, ESPEN
encourages the use of polymeric EN formulations as the primary formula of choice in
addition to oral intake (15).
According to ESPEN, indications for EN in patients with active CD include the
“prevention and treatment of undernutrition, improvement of growth and development in
children and adolescents, improvements in quality of life, acute phase therapy, perioperative nutrition [which refers to the three phases of surgery: preoperative,
intraoperative, and postoperative nutrition] and maintenance of remission in chronic
active disease” (15). Maintenance of remission in the case of persistent intestinal
inflammation can be achieved by using oral nutritional supplements (EN and
vitamin/mineral supplements). EN and oral nutritional supplements are recommended in
addition to normal food, to improve the nutritional status of the patient and to eliminate
consequences of malnutrition and growth retardation (15).
According to ESPEN, there are no significant differences between the effects “of free
amino acid, peptide-based and whole protein formulae for tube feeding” in patients with
active CD (15). Therefore, free amino acid (elemental) or peptide-based (semielemental) formulations are not recommended, unless the patient cannot tolerate the
polymeric formulation (15).
ASPEN Clinical Nutrition Guidelines for CD
The American Society for Parenteral and Enteral Nutrition (ASPEN) is an
interdisciplinary organization devoted to improving patient care by advancing the science
and practice of clinical nutrition and metabolism (20). In 2008, ASPEN published
clinical practice guidelines for IBD (16). The ASPEN guidelines emphasize that EN
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should be used in adult CD patients that require specialized nutrition support, but
specialized nutrition support and bowel rest should never be the primary therapies for
CD. This emphasizes the need to encourage intake by mouth prior to initiation of enteral
intake (tube feedings) and to provide EN as an adjunct to other therapies (medical,
surgical and pharmacological). Similar to ESPEN guidelines, ASPEN guidelines support
the use of polymeric EN formulations because EN “effectively reverses malnutrition”
(20). Additionally, both ASPEN and ESPEN guidelines state that PN should be a last
resort for patients with IBD, unless they have fistula-associated CD. However, ASPEN
does not provide recommendations on how EN should be provided to individuals with
active CD.
AND Nutrition Care Manual Guidelines for CD
The Academy of Nutrition and Dietetics (AND) publishes an online diet and professional
practice manual, the Nutrition Care Manual (NCM), that provides evidence-based
nutrition care information for various medical conditions (33). The NCM describes MNT
for patients with active CD due to the digestive issues associated with CD. The NCM
states that EN or PN “is used as a supportive mechanism when oral diet or vitamin
supplementation cannot meet nutritional needs” (33). Additionally, the guidelines state
that “formula choice will depend on [the] functional status of the [GI] tract”; however, it
does not provide detailed information on the use of EN to help promote remission and
nutritional stability in patients with active CD (33).
Current Practices of the RD in the Treatment of Patients with Active CD
The RD is important in the care of patients with disorders of the GI tract (21, 31, 34).
RDs are qualified to identify inadequate nutrient intakes in patients with IBD and to
provide individualized nutrition advice, which “improves nutritional knowledge,
nutritional intake and nutritional status in patients with intestinal failure” (35). In 2006,
the United Kingdom (UK) conducted their first national audit in the area of
gastroenterology and found that there was an unacceptably low number of RDs working
in gastroenterology, with only 37% of CD patients who have ever seen a RD (34). It is
important to utilize the RD to promote optimal nutritional status in patients with IBD, to
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prevent malnutrition and improve QOL (36). The RD is important in the treatment of
patients with active CD; however RDs are underutilized in gastroenterology in general
(34, 35). Utilizing RDs is essential in providing optimal care for patients with active CD
to improve their medical outcomes and nutritional status.

Prince et al. (28) aimed to identify and explore nutritional issues of concern to patients
with IBD and their opinions of the health services that they receive for these nutritional
issues. Seventy-two adults diagnosed with either CD (n = 47) or ulcerative colitis (n =
25) participated in this survey. Fifty-six percent were females, 56% were white and all
were older than 18 years (mean age of 39 years). The participants completed a
questionnaire that was administered via a face-to-face interview at adult outpatient
gastroenterology clinics at Guy’s and St. Thomas’ NHS Foundation Trust in the United
Kingdom. Forty-five percent of all respondents rated food and nutrition as ‘important’ or
‘extremely important’ with respect to their disease. Eighty-three percent of individuals
with CD reported experiencing problems with food and nutrition with 94% reporting
problems with body weight, specifically unintentional weight loss. Lethargy was
reported by 85% of all respondents as an issue and was often associated with iron
deficiency or poor overall nutritional intake. Half of all respondents reported that they
had consulted with an RD as part of their treatment. A limitation of this study is that the
authors did not report whether those who were referred to an RD found it to be beneficial
or had improved health outcomes. Results of this study suggest that individuals with IBD
have nutritional concerns and may avoid foods that they perceive to exacerbate their
condition, which may put them at nutritional risk for malnutrition or other nutritional
deficiencies. The investigators suggested that there is a need for RDs to provide
individualized nutritional assessment and counseling to individuals with IBD to treat
those with malnutrition or at risk for developing malnutrition as a result of their disease.
The Role of the RD in Medical Nutrition Therapy
There is limited research on the role of the RD on patient care or outcomes in the acute
care setting. The following discussion reviews studies on the skills and standards of care
provided by nutrition experts (e.g. nutritionists, RDs), prescriptive practices of RDs, and
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the positive impact that RD involvement in healthcare can have on patient and clinical
outcomes.

Due to the limited research available on practices of RDs for their patients with active
CD, a study on the practices of RDs, nutritionists and physicians in the care of PKU
patients will be discussed. In 2008, a group of investigators conducted a survey at a
meeting of the European Nutritionist Expert Panel on phenylketonuria (PKU) with
attendees from ten European centres with the aim of highlighting the key differences in
dietary management among the centres and exploring possible reasons for the differences
(37). Each centre was represented by a single RD, nutritionist or physician who
completed the survey in person at the PKU meeting. The questionnaire consisted of a set
of questions that collected information regarding the number of patients who visited each
centre, management guidelines, training background of the nutrition expert, their roles
and responsibilities, the individuals responsible for monitoring the patient’s diet,
reimbursement for monetary cost of special diets or food products, challenges associated
with disease management and policies on specific diets. The results of this study indicate
that all the European centres have different recommendations and practices regarding
nutritional therapy for PKU. A limitation of this study includes the various training and
education levels of the respondents because RDs, nutritionist and physicians have
unequal training, status and responsibilities throughout Europe. Degree courses in
dietetics are not standard and RDs and nutritionists may have different skill sets and
competencies depending on their training. It was reported that in some centres, the
physician, not the RD, prescribes the diet and the RD may only be involved in the
discussion and provision of dietary information. As a result of this study, the
investigators concluded that it would be beneficial to standardize the nutritional therapy
for PKU patients in order to provide optimal medical care. This study suggests that
practices vary among RDs and nutritionists in Europe in the nutritional therapy of PKU.
As in this study, due to the limited published literature on RD practices on patients with
active CD, it is possible that practices of RDs vary for their patients with active CD.
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Weil et al. (38) surveyed 1,500 clinical nutrition managers (CNMs), using an online
survey website. The CNMs were employed at an acute care hospital with more than 150
beds that were registered with the American Hospital Association in 2005. The purpose
of the survey was to evaluate the barriers to nutritional practices and prescriptive
authority in the hospital settings in America. Three hundred fifty-one CNMs responded
to the survey with a response rate of 23%. Fifty-four percent of respondents reported that
they had no prescriptive authority. Thirty-six percent of respondents reported dependent
prescriptive authority meaning that the RD had the authority to order diets, nutritional
supplements, nutrition-related laboratory tests or procedures, as per the facilities protocol,
but the RD could also discuss the nutritional care provided with the physician and
document the order in the medical record. Ten-percent of respondents reported
independent prescriptive authority (the RD was able to place an order without the
physician). Barriers to independent prescriptive authority included opposition from
physicians and liability issues. The investigators concluded that the majority of
respondents did not have independent prescriptive authority, but valued the ability to
have prescriptive authority. Limitations of this study included the low response rate, bias
secondary to access to technology and inability to distinguish between responders and
non-responders to the survey. In addition, respondents may have completed the survey
more than one time. This study contributed more information regarding RD prescriptive
practices and the roles of RDs in acute care settings. The results of this study indicate
that physician opposition is a main barrier to independent prescriptive authority even
though there are many benefits to increased prescriptive authority, which include: timely
implementation of nutrition-related orders, increased quality of care and recognition of
RD expertise. The researchers of this study suggested that a higher level of prescriptive
authority may require the RD to meet additional educational competencies during their
training and that future research should focus on identifying these additional
competencies necessary for higher prescriptive authority, so that a curriculum of
continuing education models could be provided to support RDs with the increased
responsibilities associated with prescriptive authority. This study highlights the
importance, benefits and barriers of the RD in achieving higher prescriptive authority.
Depending on the prescriptive authority of RDs in New Mexico, they may only be
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involved in the recommendations for EN support in their patients with active CD and
may not be involved in the initiation and management of EN in their patients with active
CD.

Soguel et al. (39) conducted a prospective interventional study to investigate the clinical
impact of a two-step interdisciplinary quality nutrition program. The study participants
included 572 patients that required greater than 72 hours in the Intensive Care Unit
(ICU). Subjects were predominately male (68%) with the mean age of 59 years. The
study intervention involved three periods: 1) baseline, 2) a bottom-up implementation of
the protocol on feeding guidelines to increase the early delivery and amount of nutrition
(calories) provided to ICU patients, and 3) the continued implementation of the feeding
guidelines protocol with the additional presence of an RD in the ICU. The daily energy
balance difference between baseline and period 3 (protocol with RD presence) was
significant (based on improved energy deficit from -5870 kcal/week to -3950 kcal/week,
p < 0.001) with the cumulative energy balances of patients improving over all three
periods. The amount of days with nutrition therapy increased significantly (59% at
baseline, 69% at implementation of bottom-up approach and 71% with the protocol in the
presence of an RD, p <.0001) with less ICU days of patients receiving nothing by mouth
or oral feeds (which were associated with decreased energy intake). The researchers
concluded that having an RD significantly improved the amount of energy provided in
order to meet the ICU patients’ energy needs due to early detection of energy deficits,
earlier introduction of nutrition therapy and the RD’s suggestion to use combined
feedings to increase the energy provided to patients. A limitation of this study was that
patients in the first period of the study (baseline) were less sick and had a lower mortality
rate, per the study investigators. Therefore, the patients in period 1 had a better chance of
receiving adequate caloric needs. The results of this study support the need for an ICU
feeding protocol and RD to manage and oversee the overall nutrition provided to ICU
patients. The implementation of the ICU feeding protocol with the involvement of the
RD improved the amount of calories provided to ICU patients. This study implies that
having an RD can significantly improve nutritional status and prevent malnutrition in the
acute care setting. It is especially important for patients with active CD to be seen by an
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RD due to their increased risk for malnutrition and weight loss and to optimize their
energy and nutrient intake.

Culkin et al. (36) evaluated the effectiveness of an intervention, which consisted of
providing nutrition education materials and dietary counseling by an RD, on
improvement in patient knowledge, oral intake, nutritional status and QOL in individuals
with chronic intestinal failure (CIF). Forty-eight patients participated in the study.
Thirty-three received home PN and an oral CIF diet, five consumed an exclusive oral CIF
diet, four received oral nutritional supplements in addition to a CIF diet, four received
home intravenous fluids and a CIF diet and two received subcutaneous fluids in addition
to a CIF diet. The average age of the participants was 56 years, with females in the
majority (65%). Patients completed baseline and post-intervention questionnaires (to
evaluate QOL and nutrition knowledge), as well as kept 3-day diet and GI-output diaries.
The RD was present when the patients completed the questionnaires to ensure that
participants were answering questions based on knowledge and not by referring to the
educational booklet on CIF. Also, the RD provided and explained the educational
booklet about CIF, nutrition and medications to the patients. The researchers found that
energy intake improved (2129 kcal/day at baseline vs. 2341 post-intervention, p < .04),
fat intake improved (93 g at baseline vs. 110 g post-intervention, p < .003) and that
patients demonstrated increased knowledge (via scores obtained from the knowledge
questionnaire on a scale of -100% to +100%) after the intervention with the RD (64.3% at
baseline vs. 80.7% post-intervention, p < 0.001). This study demonstrated that nutritional
counseling by an RD when paired with nutrition education via written materials may
significantly improve patient knowledge about nutrition and resulted in improved fat and
energy intakes in patients with CIF. However, it remains unknown if the written material
or the RD alone could produce similar results and if improved patient nutritional
knowledge led to any behavior changes or improvement in fat and energy intakes. The
researchers listed a number of factors that may affect patient knowledge, which included
the RD’s empathy, knowledge, encouragement, realism, confidentiality, importance,
explanation, listening skills, negotiation skills, time usage, non-verbal cues, appearance
and prejudice. It would be interesting if future studies could determine which factors
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affect patient knowledge more than others, so that RDs could focus on improving their
skills and effectiveness. This study demonstrates the usefulness of the RD and written
material to improve energy and fat intake and nutrition knowledge in individuals with GI
conditions. As in CIF, it is crucial that the RD be involved in the nutrition care of
patients with active CD, not only to provide the patient with information on the benefits
of using EN to prevent malnutrition and achieve remission, but to help the patient achieve
an optimal nutrition status.

These studies demonstrate that there is a need for standards of practice that are evidencebased in the field of dietetics and emphasize that the RD is essential for providing
appropriate MNT recommendations for their patients.
Conclusion
This literature review suggests that there is no difference in effectiveness of elemental
and semi-elemental EN formulations in the treatment of patients with active CD.
Additionally, polymeric EN formulations are recommended as the primary EN therapy in
the treatment of adults with active CD to help improve nutrition status by promoting
remission and aiding the prevention of weight loss and malnutrition (15, 17). This
emphasizes the importance of nutritional support in adult patients suffering from active
CD. However, there is limited published information regarding whether current
guidelines for the care of patients with CD are being utilized by RDs who provide MNT
to patients with active CD. The articles discussed in this literature review emphasize the
importance of the RD in providing MNT and nutrition education materials to improve
nutrition knowledge, as well as medical and nutritional outcomes. Additionally, it was
discussed that RDs are underutilized in the care of patients with GI conditions, but that
patients with GI conditions may value consultation with an RD. With the limited
research available on the appropriate nutritional therapy for patients with CD, it is
difficult for the RD to provide evidence-based MNT. The purpose of this research study
is to compare the EN formulations that are currently recommended in the acute care
setting by RDs in New Mexico for their patients with active CD to the current ESPEN
and ASPEN clinical nutrition guidelines.
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CHAPTER 3: METHODOLOGY
Human Research Protections
The study protocol was submitted to the University of New Mexico (UNM) Human
Research Protections Office (HRPO) and Institutional Review Board (IRB) approval was
obtained before the study commenced (Appendix A).
Survey Design
This study used a cross-sectional research design. During the spring of 2011, a pilot
survey was developed based on the ASPEN and ESPEN clinical nutrition guidelines and
EN formula company online websites (Abbott Nutrition and Nestlé Nutrition) (40, 41).
Pilot Study
Six individuals participated in the pilot survey, they included: one dietetic intern, two
UNM Nutrition Faculty Members and three RDs who were currently working at an acute
care facility in Albuquerque, New Mexico. The pilot study participants completed the
eight-question multiple-choice answer questionnaire and demographic questions via an
online survey and provided feedback via an evaluation form (Appendix B & C). The
pilot participants were given two weeks to complete the pilot questionnaire and
evaluation form. They received an initial, reminder and final e-mail with the HRPO
approved cover letter attached to each e-mail. Each e-mail described the purpose of the
study, the amount of time that the survey was expected to take and explained that by
completing the survey they indicated consent to participate in the study (Appendix D, E,
F). Based on the feedback collected from the pilot study, three questions were modified
(questions 2, 5 & 6) and an additional question was added to include a comments section.
The survey was modified to include eight multiple-choice questions about: 1) which EN
formulations are recommended for patients with active CD, 2) reasons for choosing a
particular type of EN formulation, 3) number of patients with active CD assessed
annually, 4) number of patients with active CD treated with EN support annually, 5)
clinical nutrition guidelines that RDs follow, 6) how EN is provided (sole diet, adjunct to
oral diet or adjunct to PN), 7) the situations in which EN is provided and 8) challenges
associated with providing EN to patients with active CD. The survey also included six
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questions about demographics and one question that allowed respondents to share
additional comments (Appendix G). The final online questionnaire (Appendix G) was
developed using the online Survey Monkey website (Palo Alto, CA).
Study Recruitment
The target population for this study was RDs who treat patients with active CD in an
acute care facility in New Mexico. A list of possible participants was obtained via
request from the Commission on Dietetic Registration (CDR). CDR provided a list that
included 390 RDs in New Mexico. The CDR list was screened for potential study
participants, who were selected based on specific eligibility criteria: they must be current
licensed RDs who have treated or were currently treating adult patients with active CD
(students, retirees and non-RDs were excluded), have an e-mail address that was on
record with CDR and be actively practicing in an acute care facility in New Mexico
during the spring of 2011. After screening for potential participants, 109 RDs between
the ages of 18 and 64 years were recruited to participate in this study.
One-hundred nine potential participants received a recruitment e-mail that described the
purpose of the study, the amount of time that the survey was expected to take and that by
completing the survey they consented to participate in the study (Appendix C). The
recruitment e-mail contained the link to the online survey and the HRPO approved
consent cover letter as an attachment, which indicated that by completing the
questionnaire they were consenting to participate in the study (Appendix H). Both the
survey and initial recruitment e-mail indicated that only RDs that worked with adult
patients with active CD in acute care facilities in New Mexico should participate in the
study. The RDs who were deemed eligible to participate received three e-mails in April
and May 2011 including: one initial recruitment e-mail and two reminder e-mails within
a period of three weeks explaining the purpose of the study, the importance of their
feedback, that their participation in the study was crucial to the success of the study,
reminders for them to complete the survey and that completion of the study questionnaire
was voluntary and indicated informed consent to participate in the study (Appendix D,
E, F).
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Data Collection
After modification of the questionnaire, the link to the online survey was e-mailed to the
109 RDs in the state of New Mexico who met the study CDR screening eligibility
criteria. Eligible RDs received an e-mail asking them to complete a survey on the Survey
Monkey website. The HRPO approved cover letter and link to the electronic
questionnaire were e-mailed to the RD sample in April and May of 2011. Both the email and questionnaire were used as recruitment and screening tools for the study to
ensure that participants fit the eligibility criteria. Forty-five RDs responded to the initial
and reminder e-mails indicating that they were not going to complete the survey because
they did not fit the inclusion criteria. Those RDs were deleted from the e-mail list and
not included in the study sample. Thirty-three completed surveys were screened for
eligibility by the primary investigator (NH). Ten respondents were excluded from data
analysis because they were ineligible for the study: they reported in the comments section
of the survey that they were not actively practicing dietetics, did not work in an acute
care facility, reported that they could not appropriately answer the survey questionnaire
or answered “I have not treated patients with active CD” to the first survey question.
After exclusion, survey results were entered into a Microsoft Excel spreadsheet in
preparation for statistical analysis. The final data analysis was conducted on a total of 23
respondents. Excluding potential participants who were deemed ineligible (n = 55), the
response rate to the survey was 42.6% (23 out of 54 potential respondents).
Statistical Analysis
The statistical software SPSS 21.0 (IBM Corporation, Armonk, New York) was used for
all data analysis. Statistical analyses were conducted using descriptive statistics, Fisher’s
exact, Pearson’s χ2 and Cramer’s V tests as appropriate to examine the relationship
between variables. P < .05 was considered to be statistically significant. Associations
between the reported guidelines used by RDs, the EN formulations recommended for
their patients with active CD and the RD’s age, gender, length of time practicing
dietetics, location of employment, the patient population they work with, situations in
which they recommend EN and the challenges associated with providing EN to patients
with active CD were analyzed for statistically significant associations.
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To analyze data obtained from the survey, responses were categorized into different
groups for questions 1, 7 and 8 (Table 3). Participants were allowed to choose multiple
responses for questions 1, 2, 5, 7, and 8; therefore percentages of responses may be
greater than 100%.
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Table 3: Categorization of Data for Statistical Analysis
*Question 1: EN Formulations
Recommended to Patients with Active CD
Semi-Elemental/Elemental Formulations

Polymeric Formulations

Polymeric & Elemental/Semi-Elemental
Formulations
No EN Formulation provided
*Question 7: Situations in Which EN is
Recommended in Active CD
Medical/Surgical Situations

Nutritional Issues

Formulas Recommended:

Crucial 1.5 Cal

Optimental

Pivot 1.5 Cal

Peptamen 1.5 Cal

Peptamen AF

Peptamen OS 1.5 Cal

Perative

Vital HN

Vivonex RTF

Vivonex Plus

Vivonex TEN

Diabetisource AC

Fibersource

Glucerna 1.2 Cal

Glucerna 1.5 Cal

Hi-Cal

Isosource 1.5 Cal

Jevity 1.2 Cal

Osmolite 1 Cal

Oxepa

Promote

Promote with Fiber

TwoCal HN
Both Polymeric and Semi-/Elemental
Formulas
Typically do not recommend EN for CD
All Situations










Related to Steroids
Not Mentioned By RD
*Question 8: Challenges Associated with
Managing EN for Patients with Active CD
Tolerance Issues

Abscess/Fistula
Patient’s Level of Alertness
Patient with Inflammatory Stenosis of
the Intestine
Patient is Intubated
Post-op
Pre-Surgical
Acute Inflammatory Stage with poor
intake
Not tolerating an oral diet
Poor nutrient intake with weight loss
of greater than 5%
Undernourished Patient
Patient refuses steroids
As an adjunct to steroids




n/a
All Reported Perceived Challenges

Number of
Responses
12

Percentage of
Responses
52.2%

2

8.7%

5

21.7%

4
Number of
Responses
11

17.4%
Percentage of
Responses
47.8%

18

78.3%

2

8.9%

2
Number of
Responses
15

8.9%
Percentages
of Responses
65.2%


Patient tolerance to EN

Re-establishing Oral PO

Limited Time

Fistulas
Knowledge Issues
7
30.4%

Limited Available Research

MD/Physician Resistance
Access Issues
7
30.4%

Formula Cost

Limited Formulary
Patient Attitude
8
34.8%

Patient Compliance

Patient Acceptance of EN or PN
None
2
8.7%

RD did not know

Not mentioned by RD
*Participants were able to choose more than one answer for this question. Percentages may total greater than 100%.
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CHAPTER 4: RESULTS
Participant Demographics
Of the 54 RDs in the state of New Mexico that were potentially eligible for this study, a
total of 23 participants (42.6% response rate) fit the inclusion criteria and completed the
survey. The respondent demographics (Table 4) included: 82.6% (n = 19) of respondents
were females, 91.3% (n = 21) were Caucasian and 9% (n = 2) were Hispanic/Latino,
73.9% (n = 17) were working at an urban/suburban acute care facility at the time of the
study compared to 26.1% (n= 6) at a rural location, 69.6% (n = 16) had been practicing RDs
for more than 15 years, 56.5% (n = 13) worked solely with the adult population and 43.5%

(n = 10) with both the pediatric and adult population. All respondents were between the
ages of 26 and 64 years.

Table 4: Participant Demographics
Participant

Gender

Age
(in years)

Ethnicity

Acute Care Facility
Location

Patient Population

Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian

Years
Practicing
Dietetics
1–5
16 – 30
1–5
> 30
16 – 30
6 – 15
16 – 30
16 – 30
16 – 30
> 30
6 – 15
1–5

1
2
3
4
5
6
7
8
9
10
11
12

Female
Female
Female
Female
Female
Female
Male
Female
Female
Female
Female
Female

26 – 40
41 – 64
26 – 40
41 – 64
41 – 64
41 – 64
41 – 64
41 – 64
41 – 64
41 – 64
26 – 40
26 – 40

Rural
Urban
Urban
Rural
Urban
Urban
Urban
Urban
Rural
Urban
Suburban
Suburban

Pediatric and Adult
Adult
Adult
Pediatric and Adult
Adult
Pediatric and Adult
Adult
Adult
Adult
Adult
Pediatric and Adult
Adult

13
14
15
16
17
18
19
20
21
22
23

Female
Male
Male
Female
Female
Female
Female
Female
Female
Female
Male

41 – 64
41 – 64
41 – 64
26 – 40
41 – 64
41 – 64
41 – 64
41 – 64
26 – 40
41 – 64
41 – 64

Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Hispanic/Latino
Caucasian
Caucasian
Hispanic/Latino
Caucasian

> 30
16 – 30
16 – 30
6 – 15
16 – 30
> 30
16 – 30
> 30
6 – 15
41 – 64
41 – 64

Urban
Rural
Urban
Suburban
Urban
Urban
Urban
Rural
Suburban
Urban
Rural

Adult
Pediatric and Adult
Pediatric and Adult
Pediatric and Adult
Pediatric and Adult
Adult
Adult
Adult
Pediatric and Adult
Adult
Pediatric and Adult

Participant Completion of Questionnaire
Of the 23 participants included in this study, 65% (n = 15) completed the survey within
the first week after the initial e-mail had been sent, 22% (n = 5) of participants completed

26

the survey during the second week after receiving the reminder e-mail and 13% (n = 3) of
participants completed the survey during the third week after receiving the final e-mail
reminder. This suggests that most participants respond and participate in survey research
within the first week of recruitment.
RD Practices in New Mexico
Eighty-three percent of respondents reported that they assess between one and ten
patients with active CD annually (n = 19), with only one participant (4.3%) reporting
assessing eleven or more patients with active CD annually and three respondents (13%)
reporting that they typically do not assess any CD patients annually. Sixty-five percent
(n = 15) of respondents reported that they treat one to five patients with active CD with
EN support annually and 34.8% (n = 8) of participants reported that they typically do not
treat any CD patients with EN support annually. Of the 23 RDs included in this study,
four (17.4%) respondents reported that they do not typically recommend EN for their
patients with active CD. Of the RDs that recommend EN formulations (n = 19) for their
patients with CD, 89.5% (n = 17) reported using elemental and semi-elemental
formulations and 36.8% (n = 7) reported using polymeric EN formulations for their
patients with active CD.

The ESPEN, ASPEN and AND NCM clinical nutrition guidelines were the most
commonly reported guidelines used by RDs for the nutritional assessment and MNT of
patients with CD. Approximately 26% (n = 6) of respondents reported using ASPEN
clinical nutrition guidelines, 22% (n = 5) reported using ESPEN clinical nutrition
guidelines, and 22% (n = 5) reported using AND NCM clinical nutrition guidelines.
Other guidelines reported to be used for the nutritional assessment and MNT of CD
patients consisted of: guidelines provided by the RD’s acute care facility (8.7%, n = 2)
and Critical Care guidelines (4.4%, n = 1). Based on this study’s results, the guidelines
reported to be most commonly used are the ESPEN, ASPEN and AND NCM guidelines;
however, most RDs reported that they typically use semi-elemental and elemental
formulations (52%, n = 12) for their patients with active CD.
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Most RDs reported following guidelines for the MNT of patients with active CD, with
only 34.7% (n = 8) of participants reporting that they did not follow any clinical nutrition
guidelines or did not know the guidelines that they were currently following. Forty-four
percent (n = 10) of respondents reported that they use ESPEN and ASPEN guidelines;
however use of these guidelines did not necessarily mean that participants used the
recommended standard (polymeric) formulations for their patients with CD (χ2 [1] = .765,
p = .382). However, those that reported using ASPEN guidelines were more likely to
report using polymeric EN formulations (χ2 [1] = 5.033, p = .025, effect size = .468).

RDs that reported using ASPEN guidelines were more likely to be working at an urban
location (χ2 [2] = 6.244, p = .044, effect size = .521).

Interestingly, no individuals that

work with both the adult and pediatric population reported using ASPEN guidelines (χ 2
[1] = 6.244, p = .012, effect size = .521). RDs that reported using ESPEN and ASPEN
clinical nutrition guidelines were more likely to provide EN support annually to their
patients with active CD (χ2 [1] = 9.436, p = .002, effect size = .641).

There was a statistically significant association between the number of years that the RD
has been practicing dietetics (1 – 15 years vs. 16 - 30 years or more) and the use of
ESPEN guidelines (χ2 [1] = 5.759, p = .016, effect size = .50), with RDs who reported
that they have been practicing dietetics for 15 years or less (34.8%, n = 8) being more
likely to report using ESPEN guidelines compared to RDs that have been practicing for
greater than 15 years (65.2%, n = 15).

In general, RDs reported that when they provide EN support, it is most commonly
provided as an adjunct to oral intake (56.5%, n = 13). Twenty-six percent (n = 6) of RDs
reported that they provide EN as the patient’s sole intake and 17.4% (n = 4) as an adjunct
to PN. Following ESPEN guidelines was not found to be statistically significant in
providing EN in a specific way (sole nutrition, adjunct to oral or adjunct to PN, χ2 [2] =
2.277, p = .32).

28

Forty-four percent of respondents (n = 10) reported that the “most important” reason for
helping them to determine which particular EN formulations to use was that the particular
formulation is on their hospital formulary. Thirteen percent (n = 3) of respondents
reported that the “most important” reason for helping them to determine which particular
EN formations to use was that the formulation contained a specific ingredient (Figure 1).
Figure 1: “Most Important” Reasons for Choosing a Particular EN Formulation

Percentages reflect the total number of responses for the “most important” reason for
choosing a particular EN Formulation.

Ranked as the top “important” reason for 30.4% (n = 7) of respondents was that it was an
elemental EN formulation. Tied for third place, respondents reported that both the
macronutrient content (22%, n = 5) and price of a particular EN formulation (22%, n = 5)
were their most “neutral” reasons for deciding upon an EN formulation (Table 5).
Table 5: Ranking of the Reasons Why RDs Choose a Particular EN Formulation
Reasons for Choosing a
Particular EN Formulation

"Most
Important"

"Important"

"Neutral"

"Not
Important"

"Least
Important"

Not
Ranked

Price

3 (11%)

0 (0%)

5 (24%)

1 (10%)

5 (26.3%)

9 (22%)

Contains a Specific Ingredient

5 (19%)

3 (15%)

4 (19%)

3 (30%)

1 (5.5%)

7 (17%)

Macronutrient Content

3 (11%)

3 (15%)

5 (24%)

2 (20%)

2 (10.5%)

8 (20%)

Elemental Formulation

4 (15%)

7 (35%)

2 (9.5%)

1 (10%)

5 (26.3%)

4 (10%)

Polymeric Formulation

2 (7%)

3 (15%)

4 (19%)

2 (20%)

2 (10.5%)

10 (24%)

4 (20%)
1 (4.5%)
1 (10%)
4 (21%)
3 (7%)
On Hospital Formulary
10 (37%)
Total Responses For Each
27
20
21
10
19
41
Ranking
* Participants were not required to rank each reason listed. Bolded responses indicate the top ranking for each reason.
Percentages were calculated based on the total number of responses for each ranking.
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RDs reported medical, surgical, corticosteroid, and nutritional reasons for using EN for
their patients with active CD (Figure 2). Nutritional issues were the most commonly
reported situations in which RDs reported recommending EN for their patients with
active CD (78.3%, n = 18), specifically when the patients are undernourished (69.5%, n =
16) or have a poor nutrient intake with 5% or greater weight loss (56.5%, n = 13).
Figure 2: Situations in Which EN is Recommended for Patients with Active CD

RDs reported their perceived challenges with the management of patients with active CD.
The reported challenges consisted of access, knowledge, tolerance and patient attitude
issues (Figure 3), with the greatest perceived challenges being: patient tolerance to EN
(56.5%, n = 13), followed by patient compliance (34.8%, n = 8), the cost of the EN
formulation (26.1%, n = 6) and limited research on the area of CD and EN (21.7%, n =
5). Access issues were reported by 30.4% (n = 7) of respondents; these included formula
cost (26.1%, n = 6) and limited formulary (4.3%, n = 1) at their acute care facility.
Knowledge issues were reported by 30.4% (n = 7) of respondents, which included limited
research in the area of CD (21.7%, n = 5) and physician resistance (13%, n = 3).
Tolerance issues were reported by 65.2% (n = 15) of respondents and included
intolerance to EN (60.9%, n = 14), re-establishing intake by mouth (4.3%, n = 1) and
limited time (to assess and follow-up with the patient, 4.3%, n = 1). Patient attitudes
were also reported to be an issue by 34.8% (n = 8) of participants, which included the
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patient’s compliance with EN recommendations (34.8%, n = 8) and their acceptance of
EN or PN support (4.3%, n = 1).
Figure 3: Challenges Associated with EN Management in Active CD

The χ 2 test revealed that there was a statistically significant association between where
the RD was employed and report of access challenges (χ2 [1] = 5.033, p = .025, effect size
= .468). Specifically, individuals who worked in a rural location reported more access
issues (cost of EN and limited EN formulary) than individuals who were employed at an
urban/suburban location. Practicing dietetics for less than 15 years had a statistically
significant association with being less likely to be currently practicing at an urban
location (χ2 [2] = 9.662, p = .008, effect size = .648).
Lastly, eight RDs provided additional comments on the use of EN in patients with active
CD (Appendix I). These comments discussed the need for simple, bullet-point guidelines
for use of EN in patients with active CD; as well as guidelines for the assessment,
diagnosis and MNT for these patients.
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CHAPTER 5: DISCUSSION
The purpose of this research study is to compare the current practices of RDs in New
Mexico in caring for their patients with active CD to the current ESPEN and ASPEN
clinical nutrition guidelines. Based on the results of this study, we find that the majority
of responding RDs employed at acute care facilities in New Mexico fail to follow the
current ESPEN and ASPEN clinical nutrition guidelines and recommendations for EN
support in patients with active CD.

Respondents reported that the most commonly used clinical nutrition guidelines used in
the acute care setting for the nutritional assessment and MNT for their patients with
active CD were the ASPEN, ESPEN and AND NCM clinical nutrition guidelines. RDs
that reported using ASPEN and ESPEN guidelines were more likely to report treating one
to five patients with active CD with EN support annually. Those RDs that did not report
using ESPEN or ASPEN guidelines were more likely to report that they do not use EN
support for their patients with active CD. This suggests that RDs that don’t use the
ASPEN and ESPEN clinical nutrition guidelines aren’t aware that EN support should be
used in patients with active CD.

This study revealed that RDs that have been practicing dietetics for less than 15 years
were more likely to report using ESPEN clinical nutrition guidelines. Recent dietetic
graduates may be more up-to-date with the current research in dietetics than the RDs who
have been practicing for a longer period of time. RDs who are further away from their
initial training may need continuing education in this area of EN support for CD patients.
This may also be explained by the fact that recent RDs are relying more on the available
clinical nutrition guidelines because of their lack of experience.

None of the RDs who reported following ESPEN guidelines reported using polymeric EN
formulations. ESPEN guidelines are substantially more detailed than ASPEN guidelines
in their description of providing EN support to patients with active CD. It is concerning
that those RDs that reported using ESPEN guidelines are not utilizing the polymeric EN
formulation recommendations, especially since the ESPEN guidelines are readily
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available on PubMed’s online journal database. It would be beneficial for future research
to examine why known guidelines are not being followed. For example, the guidelines
may be difficult to understand, individuals may not be aware that the guidelines exist or
other factors (access, knowledge, patient issues, etc.) may be preventing RDs from
recommending polymeric EN formulations to their patients. The results of this study
suggest that those RDs who reported using ESPEN guidelines, were also more likely to
report practicing dietetics for less than 15 years, therefore were more likely to report
access issues because they were less likely to be employed at an urban location; hence
access issues may be factors decreasing RD compliance with ESPEN guidelines.

The data collected from this study suggests that most RDs recommend semi-elemental
and elemental EN formulations when they recommend EN for their patients with active
CD. It is important that future research be conducted to evaluate the reasons why RDs
are recommending elemental and semi-elemental EN formulations more frequently than
polymeric EN formulations, because current nutrition guidelines (ESPEN and ASPEN)
recommend the use of polymeric EN formulations. Additionally, RDs reported that the
top “important” reason for choosing a particular EN formula was that it was an elemental
EN formulation. It is possible that even though polymeric formulations are the primary
EN therapy of choice, RDs may consider elemental and semi-elemental EN formulations
superior to polymeric EN formulations. One reason may be that many RDs believe that
elemental EN formulations may be better tolerated due to better absorption because of
advertising by formula companies who promote the use of their formulas for the use of
active CD due to possible malabsorptive and malnutrition issues. Also, an NG-tube may
be easily placed in the acute care setting, so palatability of the EN formulation may not
be an issue. Additionally, polymeric formulas may not be provided because research on
elemental diets has been positive, with published research demonstrating that individuals
who receive elemental diets may have decreased total bacteria per gram of feces, which
may reduce intestinal inflammation. This data suggests that even though current
nutrition guidelines recommend use of polymeric EN formulations; it appears, at least in
New Mexico, that these guidelines are not being utilized.
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On the other hand, RDs that reported using ASPEN guidelines were more likely to report
recommending polymeric EN formulations for their patients with active CD. Also, RDs
that reported using ASPEN guidelines reported that they only assessed and treated adult
patients and were more likely to be working at an urban location. It appears that those
RDs that reported using ASPEN guidelines are implementing the recommendations in the
guidelines more often than those who reported using ESPEN guidelines. This may be
because ASPEN is a membership organization and it may be doing a better job of
providing support and explanations of its guidelines or possibly those RDs employed at
urban locations have more access to the ASPEN clinical nutrition guidelines and larger,
better stocked formularies. ASPEN charges fees and requires membership in order to use
their clinical nutrition support tools. Either way, it is interesting that none of the RDs that
work with both the adult and pediatric population reported using ASPEN guidelines. It is
possible that these RDs are not aware that ASPEN provides guidelines for use in the
pediatric population. It would be beneficial for further research to be conducted to
determine why RDs that work with both pediatric and adult patient population are not
using ASPEN guidelines. It is a concern, since RDs that work with both the pediatric and
adult population made up a large percentage of the RDs that responded to the survey and
only half reported using any clinical nutrition guidelines at all.
The “most important” reason that RDs reported for choosing a particular EN formula, is
that the formula is available on their hospital formulary list. It is easier to use formulas
that are readily available on the acute care facility’s formulary. At some facilities, the
CNM decides which formulations are available on the formulary; it would be beneficial
for these individuals to be educated on ASPEN and ESPEN clinical nutrition guidelines.
Typically, formulas not listed on the acute care facility’s formulary are still available for
the RD to use. However, time and cost become issues, as the specific formula must be
ordered and shipped to the facility, which takes additional time to receive and dispense
and can increase the cost the facility spends on EN.

Most RDs reported that they provide EN as an adjunct to oral intake, rather than sole
intake or as an adjunct to PN. This suggests that EN is being provided to patients with
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active CD to improve their nutritional intake. RDs reported that situations, in which they
recommend EN to their patients with active CD include: medical, surgical, nutritional and
corticosteroid issues. The most commonly reported situation in which RDs will provide
EN support is a nutritional issue, such as an undernourished individual or an individual
with poor nutrient intake and greater than 5% weight loss. Most RDs are concerned
about the nutritional status of their patients, as it is the RD’s role to promote adequate
nutrient intake and prevent future complications through nutrition support and MNT.

RDs reported multiple challenges associated with the management of EN for their
patients with active CD. These challenges included: tolerance issues, patient’s attitude
towards EN, access issues and knowledge issues (physician resistance to use of EN and
limited available research on the use of EN in patients with active CD). The major
perceived challenge was tolerance issues: intolerance to EN and limited time to assess
and monitor patients. These issues are common at any hospital, as it is the RD’s job to
manage EN intolerances and inform the physician of current research on MNT for
specific conditions. Limited time is an issue everywhere because people are multitasking
more and have less time to complete their tasks (42). Lastly, access challenges (limited
formulary and cost of EN formulation) were more likely to be reported by RDs that were
employed in rural locations. New Mexico has a dispersed rural population. It would be
beneficial to know what is causing the specific access challenges (maybe EN
formulations are only delivered once a month, cost may be increased for EN formulations
at a rural location and other issues may be involved) in acute care facilities located in
rural locations because patient care should not be compromised due to the large distances
involved.

Some RDs who responded to the survey provided comments on EN use in their patients
with active CD. Based on their comments it appears that simple, bullet-point guidelines
could be beneficial in promoting the use of EN for patients with active CD because RDs
could use them for a reference, not only for themselves, but could provide them to the
physicians that they work with to promote the physician’s use of EN formulation
recommendations for patients with active CD.
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The results of this study suggest that RDs do not follow ESPEN and ASPEN clinical
nutrition guidelines in the care of their patients with active CD. Based on the published
literature on EN and active CD, it appears that EN is effective in preventing malnutrition
and inducing remission in patients with active CD when used in conjunction with other
therapies in the adult population. It would be beneficial for simple guidelines to be
provided to RDs through state licensure organizations, continuing educational credits or
dietetic practice groups as this would provide a way to create a more uniform standard of
practice for patients with active CD. RDs could continue to search out additional
guidelines for their patients with active CD, but they would at least be aware of what is
recommended by the state in which they are licensed.
Study Strengths
This study provides much needed information, in an area of research where there have
been few, if any published articles that have evaluated whether RDs use clinical nutrition
guidelines for their patients with active CD in the acute care setting. The major strength
of this study is that it fills a gap in the literature regarding how RDs in New Mexico
practice in the acute care setting in regards to EN recommendations for their patients with
active CD.
Study Limitations
This study has several limitations. The data collected relied on self-report via an online
survey questionnaire; therefore it is impossible to know if what RDs reported is truly how
RDs practice at their acute care facility. Additionally, multiple exclusion criteria (such
as: requiring participants to be current RDs [not students, retirees or RD eligible],
actively practicing dietetics, currently residing and working in New Mexico at an acute
care facility, registered with CDR with a working e-mail and have worked with adult
patients with active CD) were used in selecting the study participants, thereby possibly
limiting the generalizability of the study results. Generalizability is limited because of
the small sample size and limited geographic area covered, as these data only represent
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those RDs who actively provide MNT to patients with active CD in acute care facilities
in New Mexico and cannot be generalized to all RDs who treat patients with active CD.

Another limitation is that this study consisted of a very small sample size which impacts
the statistical power of a research study. Low power decreases the possibility of
detecting significant relationships between variables. In addition, a small sample size
limits the ability to conduct multivariate analysis and to control for potential confounders.

A limitation of this study is the low response rate to the survey (42.6 %). A low response
rate could be attributed to: e-mail addresses that did not work; individuals who moved out
of state, retired, changed employment or passed away; and individuals who had limited
time to complete the survey, lack of interest in the study, limited access to the internet or
reservations about participating in the study. This may hinder the generalizability and
reliability of the results. We cannot assume that the results of this survey are
representative of all RDs caring for patients with CD in acute care facilities in New
Mexico.

Based on the way the questionnaire was worded, the exact number of patients assessed
and treated with EN support annually is not known, only an estimated range of the
patients assessed and treated annually. The questionnaire provided pre-determined
ranges for the responses to the questions: “On average, how many patients with active
CD do you assess on a yearly basis?” and “On average, how many patients with active
CD do you treat with EN support on a yearly basis?”; hence, it is not known if one patient
or ten patients with active CD were assessed annually and if one or five patients with
active CD were treated with EN support annually. Allowing the RDs to respond with the
exact amount of patients with active CD assessed and treated annually, as well as the
number of patients that they generally assess and treat with EN, would have increased our
ability to use this variable in statistical analysis.
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Additional Research
More research should be conducted on a larger scale, for example on a national level, to
determine how RD’s in an acute care setting provide MNT for patients with active CD.
Future research should evaluate the reasons RDs have for not using clinical nutrition
guidelines and what MNT or EN recommendations that these RDs usually make for their
patients with active CD. Not utilizing clinical nutrition guidelines has huge implications
to the field of dietetics. RDs are taught to follow current evidence-based MNT, so why
are they not following the current clinical nutrition guidelines? Additionally, it would be
interesting to test RD awareness of clinical nutrition guidelines because it will help in
making MNT in the acute care setting more uniform. It is possible that RDs do not
understand the current clinical nutrition guidelines, there is a lack of availability of
guidelines (due to cost of obtaining guidelines or membership requirements), that RDs
are hesitant to follow guidelines, or that outside factors (access, knowledge, patient
issues, etc.) are preventing the RD from following the guidelines.

It is also possible that advertising by formula companies affects the RD’s decision when
choosing a formulary for the acute care facility for which they are employed and when
recommending EN for a patient with active CD. It would be both interesting and
beneficial for research to be conducted on the affect of advertising by formula companies
on the RD’s decision of which EN formulation to use.

Lastly, RDs employed in rural locations reported increased access issues (limited
formulary and increased cost of EN). More research could examine what is contributing
to these problems and determine ways to prevent these access issues from occurring in
the future.
Conclusion
The purpose of this study was to identify which EN formulations are currently
recommended in the acute care setting by RDs in New Mexico for their patients with
active CD and to compare these recommended formulations to the current ASPEN and
ESPEN clinical nutrition guidelines. Overall, most RDs who participated in this study
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did not follow the ESPEN and ASPEN clinical nutrition guidelines for EN support in
patients with active CD. We reject the hypothesis that RDs that work in acute care
facilities in New Mexico follow the current clinical nutrition guidelines (ASPEN and
ESPEN) and recommendations for EN support in patients with active CD.

Most RDs reported following clinical nutrition guidelines. Even though ESPEN and
ASPEN guidelines were the most commonly used guidelines reported by RDs, use of
these guidelines did not necessarily mean that RDs used the recommended standard
(polymeric) formulations for their patients with active CD.

The most commonly

recommended EN formulations by RDs were semi-elemental and elemental formulations
for patients with active CD. This suggests that the awareness of the guidelines and their
recommendations are not being translated into practice. Future research should examine
understanding of guidelines used, why semi-elemental and elemental formulations are
being recommended over polymeric formulations, ways to improve standards of practice
for EN use in patients with active CD and the health outcomes of patients with active CD
depending on the nutritional therapy that they receive during their treatment at an acute
care facility.
Addendum
ASPEN and ESPEN clinical nutrition guidelines have recently been updated. ASPEN
guidelines were updated in 2012, but the guidelines have not changed (20). ESPEN
guidelines were updated in 2011 (43). Because this study’s questionnaire was
administered prior to the update of the ASPEN and ESPEN clinical nutrition guidelines,
the guidelines that were in use during the time of this study were used as a reference for
the statistical analysis of this study (15, 26).
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APPENDICES
APPENDIX A: IRB EXEMPT APPROVAL FORM
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APPENDIX B: PILOT QUESTIONNAIRE

Enteral Nutrition
Registered Dietitian Clinical Nutrition Practices Questionnaire
Dear Respondent,
This study is being conducted by Nicole Horvath, a graduate student
and Dietetic Intern, and Deborah Cohen, an Assistant Professor and
Advisor, at the University of New Mexico. We are conducting this study
in order to better understand the practices of Clinical Registered
Dietitians who are employed in New Mexico acute care facilities.
Specifically, we are interested in the Clinical Registered Dietitian
prescriptive practices of enteral nutrition formulas for patients with active
Crohn's disease in New Mexico. This research will help Clinical
Dietitians to better understand how to treat Crohn's disease in New
Mexico. The results of this study will be provided to survey respondents
by the winter of 2011.
Since the validity of the results depend on obtaining a high response
rate, your participation is crucial to the success of this study. The
questionnaire will take approximately 5-10 minutes to complete.
Your completion of this questionnaire indicates your consent to
participate in this study. Please be assured that your responses will be
held in the strictest confidence. If the results of this study were to be
written for publication, no identifying information will be used.
We will send the compiled results in an email to you as soon as the
study is completed and compiled. Our hope is that this study may
increase your understanding of what enteral formula to prescribe to your
patients with Crohn's disease.
Thank you for your participation.
Sincerely,
Nicole Horvath
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1. When recommending an enteral nutrition product for your patients who are admitted
to the hospital with active Crohn’s disease, which of the following formula(s) do you
most often recommend? (check all that apply)
Diabetisource AC ___

Fibersource ___

Glucerna 1.0 Cal ___

Glucerna 1.2 Cal ___

Glucerna 1.5 Cal ___

HI-CAL ___

Isosource 1.5 Cal ___

Jevity 1.2 Cal ___

Optimental ___

Osmolite 1 Cal ___

Oxepa ___

Peptamen AF___

Peptamen 1.5 Cal ___

Peptamen OS 1.5 Cal ___

Peptamen with Prebio ___

Perative ___

Pivot 1.5 Cal ___

Promote ___

Promote with Fiber___

TwoCal HN ___

Vital HN ___

Vivonex Plus ___

Vivonex RTF ___

Vivonex TEN ___

Other ________________________________________ (List Specific Formula)
2. What are the reasons you choose a particular enteral formula? [Rank the following
reasons from 1 (most important) to 5 (least important)]
Price ___
Contains a specific ingredient ___
Macronutrient Content ___
Elemental Formula ___
Polymeric Formula ___
On Hospital Formulary ___
3. On average, how many patients with active Crohn’s disease do you assess yearly?
(select from ranges)
0-10 ________
11-20 ________
21-30 ________
>30

________
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4. On average, how many patients with active Crohn's disease do you treat with enteral
nutrition support yearly? (select from ranges)
0-5 ________
6-10 _______
11-20 ______
21-30 ______
>30 _______
5. Do you use clinical nutrition guidelines for the nutritional assessment and medical
nutrition therapy of Crohn’s disease patients at your facility?
Yes ___
No ___
Don’t know ___


If Yes, Which clinical guidelines to you use?
European Society for Parenteral and Enteral Nutrition (ESPEN) nutritional
guidelines ___
Guidelines provided by your acute care facility ___
Other ___ (list specific guidelines) _______________________________

6. When providing enteral nutrition support, would you say that enteral nutrition is used
primarily as means of providing the sole support of nutrition or as an adjunct to oral
intake:
Adjunct to oral intake ___
Sole source of nutrition ___
7. Enteral Nutrition is recommended during which of the following situations? (check
all that apply):
Steroid induced hormone imbalance ___
Patient refuses steroids ___
Undernourished patient ___
As an adjunct with steroids ___
Patient with inflammatory stenosis of the small intestine ___
Pre-surgical ___
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Post-operative ___
Obstruction ___
Abscess ___
Poor nutrient intake with a weight loss >5% ___
Other: Please list __________________________________________________
8. What are your perceived challenges associated with the management of patients with
active Crohn’s disease that receive Enteral Nutrition? (choose from the following list)
Limited Nutrition Research/Guidelines regarding enteral nutrition support and
Crohn’s disease ___
Cost of the enteral formula ___
Patient tolerance to Enteral Nutrition ___
Patient compliance ___
Other ___________________________________________
Demographic Questions
9. What is your gender?

Male____

Female____

10. What is your ethnicity? (select from list)
American Indian ___

Caucasian___

Hispanic or Latino___

African American___

Asian ___

Pacific Islander ___

Other: ______________
11. What is your age? 18-25___

26-40___

41-64___

65+___

12. What is the geographical location in which you work? (select from list)
Rural (pertaining to less-populated, non-urban areas) ___
Suburban (relating to the outlying part of a city or town) ___
Urban (relating to the city) ___
13. How long have you been a practicing Registered Dietitian?
1-5 years ___ 6 –15 years ___

16 – 30 years ___

30 years ___

*Thank you for completing the survey. Please click on SUBMIT to send answers to be
compiled with other survey results.
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APPENDIX C: EVALUATION OF PILOT QUESTIONNAIRE
Evaluation of Survey: Registered Dietitian Clinical Nutrition Practices

Directions:
 Please complete this evaluation form as you do the survey. Your feedback is very
valuable; please feel free to add additional comments and suggestions directly on
the survey.
 Return survey and evaluation form in the enclosed stamped envelope no later than
April 15, 2011 to Nicole Horvath. Thank you very much for your time and input.
1. How long did it take you to complete the survey?
____5-10 minutes
____10-15 minutes
____15-20 minutes
____longer than 20 minutes
2. Did you have any trouble understanding any of the questions?
____yes
____no
If yes, which questions were difficult: _____________________________
3. Would you recommend changing any of the questions?
____yes
____no
If yes, which questions would you change? __________________________
4. Are there any questions you would eliminate?
____yes
____no
If yes, which question(s) would you eliminate? ________________________
5. Are there any questions you would add?
____yes
____no
If yes, what question(s) would you add? ______________________________
6. Are there any other comments you would like to make regarding this survey?
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
_________________________________
Thank you very much for your feedback!
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APPENDIX D: INITIAL RECRUITMENT E-MAIL
Hello,
I am a graduate student and Dietetic Intern currently conducting a study via an online survey with the
help of Deborah Cohen, DCN, RD, Assistant Professor in the Nutrition Program at the University of New
Mexico. The purpose of this study is to identify the current practices of Clinical Registered Dietitians
who work with adult Crohn’s disease patients in acute care facilities in New Mexico. This survey
consists of 10 questions and should take approximately 5-10 minutes to complete. Please complete
the survey before May 13, 2011, the last day of my Dietetic Internship.
Please click on the following link to access the survey: http://www.surveymonkey.com/s/3JSZH75. The
survey is titled: “Practices of Registered Dietitians in New Mexico Regarding Enteral Nutrition in Patients
with Crohn’s disease”. This study has been approved by the University of New Mexico Institutional
Review Board. By completing this survey you are indicating your consent to participate in this study.
Thank you for your participation,
Nicole Horvath
Graduate Student & Dietetic Intern
University of New Mexico
(505)610-4623
nhorvath@unm.edu
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APPENDIX E: REMINDER E-MAIL
Hello,
If you have not already taken the opportunity to complete the survey “Practices of Registered
Dietitians in New Mexico Regarding Enteral Nutrition in Patients with Crohn’s Disease”, please
take the time now. The purpose of this study is to identify the current practices of Clinical
Registered Dietitians who work with adult Crohn’s disease patients in acute care facilities in New
Mexico. This survey consists of 10 questions and should take approximately 5-10 minutes to
complete. Please complete the survey before May 13, 2011, the last day of my Dietetic
Internship.
Click on the following link to access the survey: http://www.surveymonkey.com/s/3JSZH75. The
survey is titled: “Practices of Registered Dietitians in New Mexico Regarding Enteral Nutrition in
Patients with Crohn’s disease”. This study has been approved by the University of New Mexico
Institutional Review Board. By completing this survey you are indicating your consent to
participate in this study.
In order to have a representative sample of Clinical Registered Dietitians in New Mexico, your
participation is crucial to the success of this study.
Thank you for your participation,
Nicole Horvath
Graduate Student & Dietetic Intern
University of New Mexico
(505)610-4623
nhorvath@unm.edu
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APPENDIX F: FINAL REMINDER E-MAIL
Hello,

Over the past two weeks, I have been collecting data via a survey for a study about the
current practices of Clinical Registered Dietitians who work with adult Crohn’s disease
patients in acute care facilities in New Mexico.

If you haven't yet filled out the survey, would you please take a few minutes now to do so?
This is the last week to complete the survey. I would appreciate receiving your response by
May 13, 2011, the last day of my Dietetic Internship. You have been selected as a member
of a small survey sample and your individual response is crucial for the success of this
study. The survey should take approximately 5 to 10 minutes to complete and consists of
10 questions. This study has been approved by the University of New Mexico Institutional
Review Board. By completing this survey you are indicating your consent to participate in
this study.

Please click on the following link to access the survey:
http://www.surveymonkey.com/s/3JSZH75. The survey is titled: “Practices of Registered
Dietitians in New Mexico Regarding Enteral Nutrition in Patients with Crohn’s disease”.

If you have completed this survey, thank you very much for your assistance.

Thank you for your participation and support,

Nicole Horvath
Graduate Student & Dietetic Intern
University of New Mexico
(505)610-4623
nhorvath@unm.edu
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APPENDIX G: STUDY QUESTIONNAIRE
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APPENDIX H: APPROVED CONSENT COVER LETTER
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APPENDIX I: REGISTERED DIETITIANS’ ADDITIONAL COMMENTS
Additional Comments Reported by RDs that Work with Patients with Active CD:


“I have had only 2 patients with active Crohn’s Disease, both of which initially
required TPN r/t small bowel resections. The only reason these patients were
transitioned to EN as opposed to oral feedings was because both were too weak to
pass a swallow evaluation. And both tolerated the EN without problems. Both
had good outcomes.” [This RD reported that she used semi-elemental
formulations for these patients].



“I agree with the use of EN designed for malabsorptive conditions in severe
Crohn’s [disease]. We do not see a lot of patients, but do have them on
occasion.”



“I will prescribe a low residue diet if they [patients] are somewhat symptomatic.”



“Diet may not be as important as we once thought.”



“RD clinicians need simple, bullet-pointed guidelines on best practices on use of
enteral [nutrition] to give to physicians. Need to keep them educated with quick
info.”



“Will use it [EN] only if not tolerating oral intake.”



“I work at a level 3 trauma center for last 11 years and though we seen plenty of
Crohn’s disease [patients] we don’t see them for that only and most of the time
they do not need nutrition support. I have had one [who received nutrition
support] in the last 11 years. I have an interest in Crohn’s as my good friend was
diagnosed when we were 26. I have learned a lot from her journey and this is
why I remember this odd fact. Thanks for the study.”



“I would love to know more...I’ve only had one patient so far. I’d love some
nutrition assessment & diagnosis guidelines, support guidelines, and MNT
guidelines.” [This respondent reported in a previous question that she was using
TPN for her one patient with CD].
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